BioSpace News Archive

IDEAYA Biosciences, Inc. announced the closing of its underwritten public offering of 8,858,121 shares of its common stock at a public offering price of $18.50 per share, before underwriting discounts and commissions, and pre-funded warrants to purchase 2,020,270 shares of common stock at a public offering price of $18.4999 per pre-funded warrant, before underwriting discounts and commissions.

CooperCompanies announced it will report second quarter 2023 financial results on Thursday, June 1, 2023, at 4:15 PM ET.

CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the first quarter of 2023.

Abbott (NYSE: ABT) today announced it has completed the acquisition of Cardiovascular Systems, Inc. (CSI), a medical device company with an innovative atherectomy system used in treating peripheral and coronary artery disease.

Senseonics Holdings, Inc. announced that it plans to release its first quarter 2023 financial results after market close on Tuesday, May 9, 2023.

GoodRx Holdings, Inc. (Nasdaq: GDRX), a leading digital healthcare platform, today announced that executives from the Company will be presenting at the BofA Securities 2023 Health Care Conference in Las Vegas, NV, on Thursday, May 11, 2023 at 9:20 a.m. Pacific Time (12:20 p.m. Eastern Time).

MAIA Biotechnology, Inc. announced the closing of its previously announced public offering of 2,555,500 shares of its common stock at a public offering price of $2.25 per share, for gross proceeds of approximately $5.75 million, before deducting underwriting discounts and offering expenses.

bluebird bio, Inc. announced that the Company’s first quarter financial results, including commercial, regulatory and operational updates, will be released pre-market on Tuesday, May 9.

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for electrophysiology and the treatment of atrial fibrillation, announced today it will report financial results for the first quarter of 2023 after market close on Thursday, May 11, 2023.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming BofA Securities 2023 Healthcare Conference in Las Vegas, Nevada.